Neuroblastoma

Microenvironment provides growth factor for metastasis

Healthy bone is continuously involved in a dynamic process that includes bone deposition and bone resorption. However, when a person has cancer that spreads to the bone and bone marrow, the tissue becomes increasingly fragile, ...

Mar 17, 2015
popularity 5 comments 0

Unituxin approved for deadly pediatric cancer

(HealthDay)—Unituxin (dinutuximab) has been approved by the U.S. Food and Drug Administration to treat children with high-risk neuroblastoma, a rare cancer that most often affects children aged five and under.

Mar 11, 2015
popularity 6 comments 0

A new weapon in the fight against cancer

Where can you find the next important weapon in the fight against cancer? Just do a little navel-gazing. New research from Concordia confirms that a tool for keeping the most common forms of cancer at bay ...

Feb 18, 2015
popularity 24 comments 0

Neuroblastoma (NB) is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 cases per year in the US , and 100 cases per year in the UK . Close to 50 percent of neuroblastoma cases occur in children younger than two years old. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system or SNS. It most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.

Neuroblastoma is one of the few human malignancies known to demonstrate spontaneous regression from an undifferentiated state to a completely benign cellular appearance. It is a disease exhibiting extreme heterogeneity, and is stratified into three risk categories: low, intermediate, and high risk. Low-risk disease is most common in infants and good outcomes are common with observation only or surgery, whereas high-risk disease is difficult to treat successfully even with the most intensive multi-modal therapies available.

Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. However, since it is not a sympathetic nervous system malignancy it is a distinct clinical entity and is not to be confused with neuroblastoma.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Making waves with groundbreaking brain research

New research by Jason Gallivan and Randy Flanagan suggests that when deciding which of several possible actions to perform, the human brain plans multiple actions simultaneously prior to selecting one of ...